Alex Dahmani has degrees in Genetics, Immunology, and Business. His academic research focused on human T cell activity using an advanced humanized mouse model. Prior to working at Adaptive Biotechnologies, he worked for Columbia Technology Ventures where he helped review and commercialize new technologies invented on campus. He also started a remote patient monitoring company called Quio Technologies. At Adaptive, he works with biotech and pharma partners who use Adaptive’s immune medicine platform to discover and develop novel immunotherapies for infectious disease, autoimmunity, and oncology.